FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044289815> ?p ?o ?g. }

• W3044289815 endingPage "947" @default.
• W3044289815 startingPage "940" @default.
• W3044289815 abstract "Major gains in reducing the burden of hepatitis C are now possible because of the discovery of a cure. The prevention of premature deaths and increased workforce participation among people who are cured are likely to provide substantial indirect economic benefits. We developed an investment case for hepatitis C for the six WHO world regions, which, to our knowledge, is the first to consider both indirect and direct economic benefits in this context. Scaling up of testing and treatment to reach the 2030 WHO hepatitis C elimination targets was estimated to prevent 2·1 million (95% credible interval 1·3–3·2 million) hepatitis C-related deaths and 10 million (4–14 million) new hepatitis C virus infections globally between 2018 and 2030. This elimination strategy was estimated to cost US$41·5 billion (33·1–48·7 billion) in testing, treatment, and health care between 2018 and 2030 ($23·4 billion more than the status quo scenario of no testing or treatment scale up), with a global average of $885 (654–1189) per disability-adjusted life-year averted at 2030. Compared with the status quo scenario, the elimination scenario generated $46·1 billion (35·9–53·8 billion) in cumulative productivity gains by 2030. These indirect costs made elimination cost-saving by 2027, with a net economic benefit of $22·7 billion (17·1–27·9 billion) by 2030. This model shows that countries might be underestimating the true burden of hepatitis C and will benefit from investing in elimination. Major gains in reducing the burden of hepatitis C are now possible because of the discovery of a cure. The prevention of premature deaths and increased workforce participation among people who are cured are likely to provide substantial indirect economic benefits. We developed an investment case for hepatitis C for the six WHO world regions, which, to our knowledge, is the first to consider both indirect and direct economic benefits in this context. Scaling up of testing and treatment to reach the 2030 WHO hepatitis C elimination targets was estimated to prevent 2·1 million (95% credible interval 1·3–3·2 million) hepatitis C-related deaths and 10 million (4–14 million) new hepatitis C virus infections globally between 2018 and 2030. This elimination strategy was estimated to cost US$41·5 billion (33·1–48·7 billion) in testing, treatment, and health care between 2018 and 2030 ($23·4 billion more than the status quo scenario of no testing or treatment scale up), with a global average of $885 (654–1189) per disability-adjusted life-year averted at 2030. Compared with the status quo scenario, the elimination scenario generated $46·1 billion (35·9–53·8 billion) in cumulative productivity gains by 2030. These indirect costs made elimination cost-saving by 2027, with a net economic benefit of $22·7 billion (17·1–27·9 billion) by 2030. This model shows that countries might be underestimating the true burden of hepatitis C and will benefit from investing in elimination." @default.
• W3044289815 created "2020-07-29" @default.
• W3044289815 creator A5000337898 @default.
• W3044289815 creator A5011114707 @default.
• W3044289815 creator A5013176250 @default.
• W3044289815 creator A5023179056 @default.
• W3044289815 creator A5026835706 @default.
• W3044289815 creator A5071119117 @default.
• W3044289815 creator A5076813649 @default.
• W3044289815 creator A5082281741 @default.
• W3044289815 date "2020-10-01" @default.
• W3044289815 modified "2023-10-01" @default.
• W3044289815 title "A model of the economic benefits of global hepatitis C elimination: an investment case" @default.
• W3044289815 cites W1778848376 @default.
• W3044289815 cites W1985982900 @default.
• W3044289815 cites W1986111824 @default.
• W3044289815 cites W2048959014 @default.
• W3044289815 cites W2054052990 @default.
• W3044289815 cites W2143746931 @default.
• W3044289815 cites W2158543557 @default.
• W3044289815 cites W2185218296 @default.
• W3044289815 cites W2229638189 @default.
• W3044289815 cites W2336440969 @default.
• W3044289815 cites W2462340700 @default.
• W3044289815 cites W2734373255 @default.
• W3044289815 cites W2743338523 @default.
• W3044289815 cites W2765338291 @default.
• W3044289815 cites W2772877730 @default.
• W3044289815 cites W2776473002 @default.
• W3044289815 cites W2800410740 @default.
• W3044289815 cites W2888185171 @default.
• W3044289815 cites W2897619872 @default.
• W3044289815 cites W2899976161 @default.
• W3044289815 cites W2912830275 @default.
• W3044289815 cites W2962944274 @default.
• W3044289815 cites W2969730899 @default.
• W3044289815 cites W3010382763 @default.
• W3044289815 cites W4252307431 @default.
• W3044289815 doi "https://doi.org/10.1016/s2468-1253(20)30008-x" @default.
• W3044289815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32730785" @default.
• W3044289815 hasPublicationYear "2020" @default.
• W3044289815 type Work @default.
• W3044289815 sameAs 3044289815 @default.
• W3044289815 citedByCount "23" @default.
• W3044289815 countsByYear W30442898152020 @default.
• W3044289815 countsByYear W30442898152021 @default.
• W3044289815 countsByYear W30442898152022 @default.
• W3044289815 countsByYear W30442898152023 @default.
• W3044289815 crossrefType "journal-article" @default.
• W3044289815 hasAuthorship W3044289815A5000337898 @default.
• W3044289815 hasAuthorship W3044289815A5011114707 @default.
• W3044289815 hasAuthorship W3044289815A5013176250 @default.
• W3044289815 hasAuthorship W3044289815A5023179056 @default.
• W3044289815 hasAuthorship W3044289815A5026835706 @default.
• W3044289815 hasAuthorship W3044289815A5071119117 @default.
• W3044289815 hasAuthorship W3044289815A5076813649 @default.
• W3044289815 hasAuthorship W3044289815A5082281741 @default.
• W3044289815 hasConcept C127454912 @default.
• W3044289815 hasConcept C133425853 @default.
• W3044289815 hasConcept C145096142 @default.
• W3044289815 hasConcept C162324750 @default.
• W3044289815 hasConcept C166957645 @default.
• W3044289815 hasConcept C18903297 @default.
• W3044289815 hasConcept C205649164 @default.
• W3044289815 hasConcept C2776748549 @default.
• W3044289815 hasConcept C2779343474 @default.
• W3044289815 hasConcept C34447519 @default.
• W3044289815 hasConcept C71924100 @default.
• W3044289815 hasConcept C86803240 @default.
• W3044289815 hasConcept C99454951 @default.
• W3044289815 hasConceptScore W3044289815C127454912 @default.
• W3044289815 hasConceptScore W3044289815C133425853 @default.
• W3044289815 hasConceptScore W3044289815C145096142 @default.
• W3044289815 hasConceptScore W3044289815C162324750 @default.
• W3044289815 hasConceptScore W3044289815C166957645 @default.
• W3044289815 hasConceptScore W3044289815C18903297 @default.
• W3044289815 hasConceptScore W3044289815C205649164 @default.
• W3044289815 hasConceptScore W3044289815C2776748549 @default.
• W3044289815 hasConceptScore W3044289815C2779343474 @default.
• W3044289815 hasConceptScore W3044289815C34447519 @default.
• W3044289815 hasConceptScore W3044289815C71924100 @default.
• W3044289815 hasConceptScore W3044289815C86803240 @default.
• W3044289815 hasConceptScore W3044289815C99454951 @default.
• W3044289815 hasFunder F4320309815 @default.
• W3044289815 hasFunder F4320322858 @default.
• W3044289815 hasFunder F4320334705 @default.
• W3044289815 hasIssue "10" @default.
• W3044289815 hasLocation W30442898151 @default.
• W3044289815 hasLocation W30442898152 @default.
• W3044289815 hasOpenAccess W3044289815 @default.
• W3044289815 hasPrimaryLocation W30442898151 @default.
• W3044289815 hasRelatedWork W2033865017 @default.
• W3044289815 hasRelatedWork W2040681717 @default.
• W3044289815 hasRelatedWork W2136166061 @default.
• W3044289815 hasRelatedWork W2144741702 @default.
• W3044289815 hasRelatedWork W2966209494 @default.
• W3044289815 hasRelatedWork W3128301043 @default.
• W3044289815 hasRelatedWork W3145245184 @default.

• next